Advertisement

Clinical Treatment in Colorectal Cancer: Other Aspects

Chapter

Abstract

In this chapter we will discuss current concepts in the treatment of colorectal cancer (CRC)—surgery, chemotherapy, and radiotherapy. We will explain how to choose the adequate treatment approach and answer the following questions: When complete surgical removal is indicated, should chemotherapy be applied before, or instead after, the surgery? Is radiotherapy an option in colorectal cancer? We will widely discuss the surgical approaches in the CRC and currently available drugs (their medical indications, mechanism of action, spectrum of adverse effects). Moreover, we will delineate further perspectives in the CRC management—DNA sequencing, the role of small interfering RNA, and microRNA.

Keywords

Colorectal cancer Colorectal cancer chemotherapy Colorectal cancer radiotherapy 

Abbreviations

5-FU

5-Fluorouracil

CEA

Carcinoembryonic antigen

CRC

Colorectal cancer

EGFR

Epidermal growth factor receptor

FDA

Food and Drug Administration

FLOX

Double-action formula of 5-fluorouracil and oxaliplatin

FOLFIRI

Triple-action formula of 5-fluorouracil, leucovorin, and irinotecan

FOLFOX

Triple-action formula of 5-fluorouracil, leucovorin, and oxaliplatin

LV

Leucovorin

mCRC

Metastatic colorectal cancer

VEGF

Vascular endothelial growth factor

Notes

Acknowledgments

The authors have no conflicts of interest to disclose.

Supported by grants from the Medical University of Lodz (502-03/1-156-04/502-14-297 to MZ), National Science Centre (#UMO-2013/11/N/NZ7/00724 and UMO-2014/12/T/NZ7/00252 to MZ), and Ministry of Science and Higher Education (Iuventus Plus 5 Program #IP2015 089474 to MZ). AJ and MZ are recipients of the Polish L’Oréal-UNESCO Awards for Women in Science. MZ is a recipient of Polpharma Scientific Foundation Scholarship.

References

  1. 1.
    Sievers CK, Kratz JD, Zurbriggen LD, Loconte NK, Lubner SJ, Uboha N, et al. The multidisciplinary management of colorectal cancer: present and future paradigms. Clin Colon Rectal Surg. 2016;1(212):232–8.CrossRefGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network. Colon Cancer (version 2.2017) [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf [cited 20 Jul 2005].
  3. 3.
    FOxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13(11):1152–60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204512703480 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345(8955):939–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7715291 CrossRefGoogle Scholar
  5. 5.
    Pardini B, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011;72(1):162–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21204909 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006;32(7):491–503. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16959432 CrossRefPubMedGoogle Scholar
  7. 7.
    Rothenberg ML. Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology. 2000;14(12 Suppl 11):9–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11204666 PubMedGoogle Scholar
  8. 8.
    Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer. 1989;63(6 Suppl):995–1007. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2645044 CrossRefPubMedGoogle Scholar
  9. 9.
    Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res. 2011;3:79–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21629830 PubMedPubMedCentralGoogle Scholar
  10. 10.
    Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19923864 CrossRefPubMedGoogle Scholar
  11. 11.
    McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68(4):487–506. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18318567 CrossRefPubMedGoogle Scholar
  12. 12.
    Weber J, McCormack PL. Panitumumab: in metastatic colorectal cancer with wild-type KRAS. BioDrugs. 2008;22(6):403–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18998757 CrossRefPubMedGoogle Scholar
  13. 13.
    National Cancer Institute at the National Institutes of Health. FDA Approval for Cetuximab. 2013. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-cetuximab
  14. 14.
    Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. doi: 10.1016/S0140-6736(12)61900-X.CrossRefPubMedGoogle Scholar
  15. 15.
    Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8(3):230–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27239240 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    National Cancer Institute at the National Institutes of Health. Trifluridine and Tipiracil Hydrochloride. 2015. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/trifluridine-tipiracilhydrochloride
  17. 17.
    FDA approves new oral medication to treat patients with advanced colorectal cancer. 2015; Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm
  18. 18.
    FDA Approval for Ziv-Aflibercept. 2013. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-ziv-aflibercept
  19. 19.
    De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21163703 CrossRefPubMedGoogle Scholar
  20. 20.
    Bäumer S, Bäumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, et al. Antibody-mediated delivery of anti–KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Cancer Res. 2015;21(6):1383–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of MicroRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385–92. Available from: http://www.nature.com/doifinder/10.1038/onc.2008.474 CrossRefPubMedGoogle Scholar
  23. 23.
    Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18(3):244–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22647361%5Cn; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3397427 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bartos A, Bartos D, Szabo B, Breazu C, Opincariu I, Mironiuc A, et al. Recent achievements in colorectal cancer diagnostic and therapy by the use of nanoparticles. Drug Metab Rev. 2016;2532(February):1–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26828283 Google Scholar
  25. 25.
    Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15067028 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of MedicineMedical University of LodzLodzPoland

Personalised recommendations